ライフサイエンスコーパス: nosocomial

1 NoV infections in hospitalized patients were nosocomial.

2 aureus is a leading cause of community- and nosocomial-acquired infections, with a propensity for bi

3 le-genome sequencing was used to demonstrate nosocomial acquisition of antimicrobial-resistant sequen

4 the initial set, no hemodialysis dependence, nosocomial acquisition of S. aureus bacteremia, absence

5 inosa bacteremia were prior transplantation, nosocomial acquisition, and septic shock at onset.

6 the leading cause of community-acquired and nosocomial acute gastroenteritis.

7 or the early diagnosis of difficult-to-treat nosocomial and community acquired clinical infections an

8 hylococcus aureus is a leading cause of both nosocomial and community-acquired infection.

9 ution of NoV genotypes among inpatients with nosocomial and community-acquired NoV infections, respec

10 evasive factors contribute to the success of nosocomial and community-associated clonal lineages, aid

11 multidrug-resistant fungal pathogen causing nosocomial and invasive infections associated with high

12 vors succumb later to persistent, recurrent, nosocomial, and secondary infections, many investigators

13 We focused on cases involving a major nosocomial-associated strain, L. pneumophila sequence ty

14 One of the the most dominant nosocomial bacteria, Methicillin Resistant Staphylococcu

15 r the most important causes of community and nosocomial bacterial meningitis based on International C

16 nity skin and soft tissue infections than in nosocomial bloodstream infections (11.1% versus 5.6%, re

17 is unknown whether rising incidence rates of nosocomial bloodstream infections (BSIs) caused by antib

18 Increased nosocomial BSI rates due to ARB occur in addition to inf

19 33 130 nosocomial BSIs (14% caused by ARB) yielded 36 679 micro

20 PVCs accounted for a mean of 6.3% and 23% of nosocomial BSIs and nosocomial catheter-related BSIs, re

21 nsities (events per 100 000 patient-days) of nosocomial BSIs caused by methicillin-resistant Staphylo

22 ated the effects of asymptomatic carriers on nosocomial C difficile infections.

23 Two proven nosocomial cases of Legionella pneumonia occurred at the

24 to resolve the infection source in possible nosocomial cases, we aimed to determine whether whole-ge

25 mean of 6.3% and 23% of nosocomial BSIs and nosocomial catheter-related BSIs, respectively.

26 prevalence, acquisition rates, and incident nosocomial clinical culture (INCC) rates, each a surroga

27 Nosocomial clones, including epidemic sequence type 258

28 pneumonia and influenza are associated with nosocomial Clostridium difficile infection (CDI) inciden

29 Rates of nosocomial Clostridium difficile infection were compared

30 orbidity and mortality rates associated with nosocomial Clostridium difficile-associated diarrhea (CD

31 sistent regarding their efficacy in reducing nosocomial complication rates.

32 ssociation between documentation cohorts and nosocomial complications.

33 whether checklist usage was associated with nosocomial complications; when documented, elements were

34 During the intervention, nosocomial CRE acquisition in acute care declined from a

35 CDI, 36 subjects with C. difficile-negative nosocomial diarrhea (CDN), and 40 healthy control subjec

36 e is the most frequently identified cause of nosocomial diarrhea and has been associated with epidemi

37 sease (CDAD) constitutes a large majority of nosocomial diarrhea cases in industrialized nations and

38 idium difficile remains the leading cause of nosocomial diarrhea worldwide, which is largely consider

39 Clostridium difficile is a major cause of nosocomial diarrhea, with 30-day mortality reaching 30%.

40 difficile is the leading cause of infectious nosocomial diarrhea.

41 infection is a serious and highly prevalent nosocomial disease in which the two large, Rho-glucosyla

42 for the enhanced surveillance and control of nosocomial E. faecium transmission and infection.

43 tion of patients with health care-associated nosocomial endocarditis decreased (from 17.7% to 15.3%;

44 , and (iii) persistence in patients and in a nosocomial environment.

45 a significant economic and health burden in nosocomial environments.

46 o rely on contact precautions for preventing nosocomial ESBL-EC transmission in nonepidemic settings,

47 Nosocomial EVD transmission risk may be lower than feare

48 study primary outcome or incidence of common nosocomial gastrointestinal and respiratory tract infect

49 tify the contribution of opioid tampering to nosocomial HCV outbreaks, data from health care-related

50 During a nosocomial hepatitis C outbreak, emergency public clinic

51 transcriptomic response of a representative nosocomial human pathogen, Acinetobacter baumannii, to c

52 [95% CI, 1.07-1.32], P = .001); presence of nosocomial infection (OR = 36.3 [95% CI, 9.71-135.96], P

53 ificantly greater in patients that developed nosocomial infection and organ dysfunction than similarl

54 The associations between nosocomial infection and patient age, sex, and NoV genot

55 eumoniae, which are frequently implicated in nosocomial infection and preterm infant gut colonization

56 m difficile infection is a relatively common nosocomial infection in mechanically ventilated patients

57 lthcare settings, yet the greatest burden of nosocomial infection occurs in resource-restricted setti

58 Nosocomial infection of health-care workers (HCWs) durin

59 Nosocomial infection was mainly associated with older ag

60 55 years, 52% hepatitis C virus [HCV], 15.8% nosocomial infection, 96% Child score >/= 7) and 30-day

61 shock, while the onset of the effect of age, nosocomial infection, and cirrhosis was later.

62 HRS were age, high baseline serum bilirubin, nosocomial infection, and reduction in serum creatinine

63 aureus nasal carriage and increased risk of nosocomial infection, as well as increased carriage due

64 Nosocomial infection, organ failure, and mortality in th

65 te measure of importation, transmission, and nosocomial infection, respectively.

66 though classically thought to be primarily a nosocomial infection, the incidence of community-acquire

67 ridium difficile colitis, a leading cause of nosocomial infection, was studied in humans and in a mur

68 hylococcus aureus (MRSA) is a major cause of nosocomial infection.

69 coccus faecium (VREfm) is a leading cause of nosocomial infection.

70 tobacter baumannii is a significant cause of nosocomial infection.

71 s associated with an increased risk for VLBW nosocomial infection.

72 r developing fecal carriage that may lead to nosocomial infection.

73 ated with levels of the type 2 cytokines and nosocomial infection.

74 e L. pneumophila population as the source of nosocomial infection.

75 ated ventilator-associated complication were nosocomial infections (27.3% and 43.8%), including venti

76 taxa containing species that commonly cause nosocomial infections (e.g., Enterobacteriaceae) that we

77 that renders trauma patients susceptible to nosocomial infections (NI) and prolonged intensive care

78 interval 1.96-53.32), and the development of nosocomial infections (p < 0.05, Mann-Whitney U test).

79 CI, 0.68-1.90; I = 51.6%) and acquisition of nosocomial infections (relative risk, 1.13; 95% CI, 0.61

80 ference was found for the duration of common nosocomial infections [mean (range): 3.58 (1-7) vs. 3.79

81 esponsible for large numbers of postsurgical nosocomial infections across the United States and world

82 These are associated with higher rates of nosocomial infections among infants with very low birth

83 unsaturated fatty acids on the prevalence of nosocomial infections and clinical outcomes in medical a

84 yunsaturated fatty acids reduces the risk of nosocomial infections and increases the predicted time f

85 ient transfers, contributes to the spread of nosocomial infections and investigate how network struct

86 Acinetobacter baumannii frequently causes nosocomial infections and outbreaks.

87 1 are associated with a higher incidence of nosocomial infections and seem to be major actors of sep

88 intervention to help reduce the incidence of nosocomial infections and sepsis postburn.

89 blood transfusions had a higher incidence of nosocomial infections and sepsis, and the amount of bloo

90 Many nosocomial infections arise from gastrointestinal coloni

91 ted readmissions consistently had index-stay nosocomial infections as a predictor for HE, renal/metab

92 ts with advanced cirrhosis and prevention of nosocomial infections could reduce this burden.

93 covering from inpatient vascular surgery and nosocomial infections did not occur.

94 logy, risk factors, and impact on outcome of nosocomial infections during extracorporeal membrane oxy

95 B. animalis subsp. lactis failed to prevent nosocomial infections in an acute-setting pediatric hosp

96 The incidence of nosocomial infections in children in developed countries

97 cterium animalis subsp. lactis in preventing nosocomial infections in the acute hospital setting.

98 importation and transmission influence MRSA nosocomial infections in Veterans Affairs Medical Center

99 osuppression and increased susceptibility to nosocomial infections observed in critically ill sepsis

100 Nosocomial infections pose a significant threat to patie

101 Furthermore, nosocomial infections such as invasive aspergillosis and

102 ptococcus pneumoniae is a causative agent of nosocomial infections such as pneumonia, meningitis, and

103 for Disease Control and Prevention National Nosocomial Infections Surveillance.

104 ostridium difficile is the cause of emerging nosocomial infections that result in abundant morbidity

105 The prevalence of nosocomial infections was detected during 28 days of ICU

106 n into account that the overall incidence of nosocomial infections was lower than expected.

107 The number of patients with nosocomial infections was significantly reduced in the f

108 Nosocomial infections were defined as infections that oc

109 of </= 20 TIPS/year, variceal bleeding, and nosocomial infections were independent risk factors for

110 BACKGROUND & AIMS: Nosocomial infections with Clostridium difficile present

111 Nosocomial infections with Klebsiella pneumoniae are a f

112 Enterococci are the leading cause of nosocomial infections worldwide and acquired resistance

113 , known to cause both community-acquired and nosocomial infections worldwide.

114 ulitis are projected to cause more than 9000 nosocomial infections, 1000 to 5000 Clostridium difficil

115 frequency of shock reversal, acquisition of nosocomial infections, and changes in body temperature,

116 ient and family verbal abuse, patient falls, nosocomial infections, and medications errors.

117 Pseudomonas aeruginosa is a leading cause of nosocomial infections, and resistance to virtually all a

118 nterobacter, genera commonly associated with nosocomial infections, dominate the preterm infant gut m

119 tors underlying the outcome of P. aeruginosa nosocomial infections, including aspects related to the

120 dent predictors for development of ACLF were nosocomial infections, Model for Endstage Liver Disease

121 Enterococcus faecium is a common cause of nosocomial infections, of which infective endocarditis i

122 ginosa is among the leading causes of severe nosocomial infections, particularly affecting critically

123 nt-line antibiotic used for the treatment of nosocomial infections, particularly those caused by meth

124 sed percentages of blood MDSCs had increased nosocomial infections, prolonged intensive care unit sta

125 rging pathogen that causes a wide variety of nosocomial infections, spreads rapidly within hospitals,

126 ve bacterium responsible for a wide range of nosocomial infections.

127 responsible for up to 10% of gram-negative, nosocomial infections.

128 56 inpatients, 63% were classified as having nosocomial infections.

129 A) which is one of the most common causes of nosocomial infections.

130 shock and correlated to adverse outcomes or nosocomial infections.

131 ic fibrosis patients and is a major agent of nosocomial infections.

132 ents were used to estimate the proportion of nosocomial infections.

133 V infections were more heterogeneous than in nosocomial infections.

134 sociated with an increased susceptibility to nosocomial infections.

135 e a modifiable risk factor for postoperative nosocomial infections.

136 ity of pathogens to evolve in the context of nosocomial infections.

137 y related species are commonly implicated in nosocomial infections.

138 ticular, is now one of the leading causes of nosocomial infections.

139 which is responsible for the development of nosocomial infections.

140 ida species are one of the leading causes of nosocomial infections.

141 n immune function can predispose patients to nosocomial infections.

142 humans, and is one of the leading causes of nosocomial infections.

143 an opportunistic pathogen that causes severe nosocomial infections.

144 medical environment and causes severe human nosocomial infections.

145 ticularly high-risk population to intestinal nosocomial infections.

146 s responsible for approximately one-third of nosocomial infections.

147 ere associated with subsequent occurrence of nosocomial infections.

148 dysfunction responsible for poor outcome and nosocomial infections.

149 cost-effective mechanism to monitor emerging nosocomial infections.

150 testinal tract (GIT) and an agent of serious nosocomial infections.

151 ndependently associated with higher risk for nosocomial infections.

152 a L. pneumophila population responsible for nosocomial infections.

153 ingly been recognized as a major pathogen in nosocomial infections.

154 evices, it has emerged as a leading cause of nosocomial infections.

155 h, sexually transmitted infections and major nosocomial infections.

156 iated with cirrhosis severity, diabetes, and nosocomial infections; close monitoring of patients with

157 infection (CDI) is the most common cause of nosocomial infectious diarrhea and may result in severe

158 stridium difficile is the principal cause of nosocomial infectious diarrhea worldwide.

159 pproach is imperative to control and prevent nosocomial influenza in health-care settings.

160 in-resistant Staphylococcus aureus (MRSA) in nosocomial investigations and epidemiological studies bu

161 ments were found at a higher frequency among nosocomial isolates.

162 ations, rather than acquisition of resistant nosocomial isolates.

163 This case study confirms that the typically nosocomial lineage (E-MRSA15) can transmit within commun

164 d thus may facilitate airway colonization in nosocomial lung infections.

165 further performed whole-genome sequencing of nosocomial MDRPa strains to evaluate genotypic relations

166 pathogen close to common bacterial causes of nosocomial meningitis such as staphylococcus and Gram-ne

167 acquired, 56% healthcare associated, and 20% nosocomial) met study criteria.

168 h recently emerged as global pathogens, with nosocomial mortality rates reaching 19-54%.

169 g transmission contributed to lower rates of nosocomial MRSA infection.

170 the study was to estimate the proportion of nosocomial NoV infections among inpatients testing posit

171 Nosocomial NoV infections were associated with age >/=60

172 e species within the Acinetobacter genus are nosocomial opportunistic pathogens of increasing relevan

173 Acinetobacter baumannii is an emerging nosocomial, opportunistic pathogen that survives desicca

174 smission events, delimit the extent of local nosocomial or community-based outbreaks, and identify wo

175 ion of genotype 1a before 1965 suggests that nosocomial or iatrogenic factors rather than past sporad

176 ading pathogens and were more susceptible to nosocomial organisms, or both.

177 tes belonging to ST14 were isolated during a nosocomial outbreak from 6 patients.

178 nd HSV, the viruses commonly associated with nosocomial outbreaks in eye care.

179 Health-care workers have been implicated in nosocomial outbreaks of Staphylococcus aureus, but the d

180 rtionately, many cases of HCV infection from nosocomial outbreaks were attributable to provider tampe

181 he hypervirulent clade 2 are responsible for nosocomial outbreaks worldwide.

182 ct the health of patients by preventing such nosocomial outbreaks.

183 The nosocomial pathogen Acinetobacter baumannii is a frequen

184 Staphylococcus aureus is a prominent nosocomial pathogen and a major cause of biomaterial-ass

185 Clostridium difficile is an important nosocomial pathogen and the leading cause of antibiotic-

186 Clostridium difficile is a major nosocomial pathogen and the main causative agent of anti

187 Acinetobacter baumannii is a common nosocomial pathogen capable of causing severe diseases a

188 dium difficile is the most commonly reported nosocomial pathogen in the United States and is an urgen

189 spore-forming obligate anaerobe and a major nosocomial pathogen of worldwide concern.

190 n important role in driving the evolution of nosocomial pathogen populations.

191 is their superior activity against the major nosocomial pathogen Pseudomonas aeruginosa.

192 as maltophilia is an emerging, opportunistic nosocomial pathogen that can cause severe disease in imm

193 against Clostridium difficile, an important nosocomial pathogen that causes highly infectious diarrh

194 r baumannii is a Gram-negative opportunistic nosocomial pathogen that causes pneumonia and soft tissu

195 tobacter baumannii is a globally distributed nosocomial pathogen that has gained interest due to its

196 Acinetobacter baumannii is an emerging, nosocomial pathogen that is poorly characterized due to

197 ococcus aureus (MRSA) has emerged as a major nosocomial pathogen that is widespread in both health-ca

198 Acinetobacter baumannii is an important nosocomial pathogen that often affects critically ill pa

199 Clostridium difficile is a major nosocomial pathogen that produces two exotoxins, TcdA an

200 Pseudomonas aeruginosa is a common nosocomial pathogen that relies on three cell-to-cell si

201 nterococcus faecalis (VREfs) is an important nosocomial pathogen(1,2).

202 dium difficile is a significant concern as a nosocomial pathogen, and genetic tools are important whe

203 infections, due to Staphylococcus aureus, a nosocomial pathogen, is still in its nascent stages.

204 Clostridium difficile is a prominent nosocomial pathogen, proliferating and causing enteric d

205 ia is a ubiquitous bacterium and an emerging nosocomial pathogen.

206 to study the mode of action of this emerging nosocomial pathogen.

207 o better means of controlling this important nosocomial pathogen.

208 Acinetobacter baumannii is an important nosocomial pathogen.

209 cient biofilm former and a commonly isolated nosocomial pathogen.

210 nterococcus faecalis (VREfs) is an important nosocomial pathogen1,2.

211 ous protein found in strains of the emerging nosocomial pathogens Acinetobacter nosocomialis and Acin

212 stridium difficile is one of the most common nosocomial pathogens and the cause of pseudomembranous c

213 Early detection of new or novel variants of nosocomial pathogens is a public health priority.

214 ability of providers to match treatment with nosocomial pathogens is unknown.

215 Multidrug-resistant nosocomial pathogens present a major burden for hospital

216 s to accurately match antibiotic coverage to nosocomial pathogens remains low.

217 cus faecalis are highly antibiotic-resistant nosocomial pathogens that use the mechanism of conjugati

218 d intermediates against a panel of bacterial nosocomial pathogens was performed.

219 tinel hospital surveillance system for novel nosocomial pathogens, delivering early detection times f

220 l surfaces may contribute to transmission of nosocomial pathogens.

221 biotics for pneumonia despite no increase in nosocomial pathogens.

222 truction and greater risk of colonization by nosocomial pathogens.

223 tibiotics for patients with risk factors for nosocomial pathogens.

224 d here, to help them control these important nosocomial pathogens.

225 -resistant Enterobacter species are emerging nosocomial pathogens.

226 lay an important role in the transmission of nosocomial pathogens.

227 logical surveillance of multi-drug resistant nosocomial pathogens.

228 ost important and problematic, opportunistic nosocomial pathogens.

229 case of severe falciparum malaria following nosocomial Plasmodium falciparum transmission in nonende

230 was lower in brain-injured patients without nosocomial pneumonia (1% [range: 0%-7%]) and in brain-in

231 compared with brain-injured patients without nosocomial pneumonia (16% [range: 6%-29%]) and with heal

232 tly decreased in brain-injured patients with nosocomial pneumonia (3% [range: 1%-9%]) compared with b

233 s not altered in brain-injured patients with nosocomial pneumonia (31% [range: 12%-44%]).

234 : 0%-7%]) and in brain-injured patients with nosocomial pneumonia (4% [range: 2%-5%]) compared with h

235 increased in brain-injured patients without nosocomial pneumonia (66% [range: 34%-69%]) compared wit

236 Adults with nosocomial pneumonia (including ventilator-associated pn

237 alternative to carbapenems in patients with nosocomial pneumonia (including ventilator-associated pn

238 dults admitted to an index hospital with non-nosocomial pneumonia (January through December 2010) and

239 role of periodontitis in the development of nosocomial pneumonia (NP) have been published, the debat

240 3; 95% CI, -0.51, 4.56; p = 0.12; I = 0%) or nosocomial pneumonia (odds ratio, 0.83; 95% CI, 0.28, 2.

241 tamine 2 receptor antagonists in the risk of nosocomial pneumonia (relative risk 1.06; 95% confidence

242 of doripenem in critically ill patients with nosocomial pneumonia and then to use Monte Carlo dosing

243 compared with brain-injured patients without nosocomial pneumonia and with healthy donors.

244 clear cells from brain-injured patients with nosocomial pneumonia generated significantly fewer matur

245 have been associated with increased risk for nosocomial pneumonia in hospitalized patients.

246 Nosocomial pneumonia is commonly associated with antimic

247 secondary outcomes were ICU length of stay, nosocomial pneumonia, and adverse events.

248 ty of ceftazidime-avibactam in patients with nosocomial pneumonia, including ventilator-associated pn

249 Klebsiella pneumoniae, a chief cause of nosocomial pneumonia, is a versatile and commonly multid

250 tiple clinical descriptions of S. marcescens nosocomial pneumonia, little is known regarding the mech

251 MEDI4893 and MEDI3902, for the prevention of nosocomial pneumonia.

252 illin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia.

253 an etiologic agent of community-acquired and nosocomial pneumonia.

254 ions between MRSA virulence and mortality in nosocomial pneumonia.

255 R Acinetobacter infections, particularly for nosocomial pneumonia.

256 d patients, and assessed its relationship to nosocomial pneumonia.

257 of selenium on ICU length of stay or risk of nosocomial pneumonia.

258 on-inferior to meropenem in the treatment of nosocomial pneumonia.

259 viders caring for hospitalized patients with nosocomial pneumonia.

260 e have positive effects on the prevention of nosocomial pneumonias.

261 ost important enteropathogen involved in gut nosocomial post-antibiotic infections.

262 r healthcare-associated pneumonia, risks for nosocomial Pseudomonas pneumonia, and associations betwe

263 ents are susceptible to infections caused by nosocomial respiratory pathogens at least in part becaus

264 ration sequencing, was used to investigate a nosocomial respiratory syncytial virus-B (RSV-B) outbrea

265 Of the latter, 27.6% had a nosocomial RV infection in PreVP, and 19.3% in PostVP.

266 Overall, the proportion of nosocomial RV infections increased from 5.5% in PreVP to

267 In older patients, heightened awareness of nosocomial RV infections is warranted.

268 uired S aureus infections, and 132 (17%) had nosocomial S aureus infections.

269 eplace conventional methods for detection of nosocomial S. aureus transmission.

270 healthcare-associated SAB, and 7% (9/136) in nosocomial SAB.

271 fective than ceftazidime in the treatment of nosocomial SBP (86.7 vs. 25%; P < 0.001).

272 Patients with cirrhosis and nosocomial SBP were randomized to receive meropenem (1 g

273 ed a broader spectrum antibiotic regimen for nosocomial SBP, according to the high rate of bacteria r

274 azidime as empirical antibiotic treatment of nosocomial SBP.

275 mycin versus ceftazidime in the treatment of nosocomial SBP.

276 redictor of 90-day survival in patients with nosocomial SBP.

277 eneration cephalosporins in the treatment of nosocomial SBP.

278 Prevention of nosocomial spread currently focuses on spread by hand an

279 Tracking the nosocomial spread of resistant bacteria is critical to i

280 Nosocomial spread was suspected solely because of the hi

281 and inexpensive intervention that may reduce nosocomial spread.

282 What is the relative importance of nosocomial transmission compared with community-acquired

283 Recently, the significance of nosocomial transmission has been challenged by screening

284 The risk of nosocomial transmission is high for patients and staff a

285 d hospital system may have contributed to no nosocomial transmission occurring during the treatment o

286 costs, clinical consequences, and impact on nosocomial transmission of treating and/or isolating pat

287 of whole viral genome sequencing to identify nosocomial transmission of varicella-zoster virus with f

288 care workers; among the health care workers, nosocomial transmission was implicated in 12 patients (3

289 In addition, findings indicated that nosocomial transmission within health facilities helped

290 rveillance, increased zoonotic transmission, nosocomial transmission, and changes in viral transmissi

291 the same otherwise rare alleles, suggesting nosocomial transmission.

292 patients, thereby reducing the potential for nosocomial transmission.

293 gically unchanged viruses in connection with nosocomial transmission.

294 bled us to establish the likely direction of nosocomial transmission.

295 onnectedness allowed multiple generations of nosocomial transmission.

296 ion needs to be balanced against the risk of nosocomial transmission.

297 lomic fingerprint has the potential to track nosocomial transmissions.

298 c in C. elegans, and a similar mutant of the nosocomial V583 isolate showed significantly attenuated

299 am antimicrobial in the previous 30 days, or nosocomial VGS BSI onset.

300 ility of whole-genome sequencing in defining nosocomial VREfm transmission.